Variable | Vancomycin & Cefazolin (nā=ā1,437) | Cefazolin (nā=ā1,470) | P-value | ||
---|---|---|---|---|---|
n | % | n | % | ||
Age (years) | 62 | Ā | 62 | Ā | Ā |
BMI (kg/m2) | |||||
āBMIā<ā20 | 16 | 1.1% | 32 | 2.2% | 0.020 |
ā20ā<āBMIā<ā30 | 543 | 37.8% | 461 | 31.4% | ā<ā0.001 |
ā30ā<āBMIā<ā40 | 546 | 40.0% | 570 | 38.8% | 0.508 |
āBMIā>ā40 | 170 | 11.8% | 180 | 12.2% | 0.740 |
Gender | |||||
āFemale | 809 | 56% | 801 | 54% | 0.279 |
āMale | 628 | 44% | 669 | 46% | 0.279 |
Race | |||||
āAmerican Indian or Alaska Native | 4 | 0.3% | 7 | 0.5% | 0.394 |
āAsian | 6 | 0.4% | 27 | 1.8% | ā<ā0.001 |
āBlack or African American | 695 | 48.4% | 637 | 43.3% | 0.006 |
āWhite | 554 | 38.6% | 745 | 50.7% | ā<ā0.001 |
āPacific Islander | 1 | 0.1% | 1 | 0.1% | 0.999 |
āUnknown | 8 | 0.6% | 22 | 1.5% | 0.018 |
āMultiple | 31 | 2.2% | 31 | 2.1% | 0.853 |
Joint | |||||
āHip | 719 | 50.0% | 732 | 49.8% | 0.914 |
āKnee | 718 | 50.0% | 738 | 50.2% | 0.914 |
Alcohol Abuse | 451 | 31.4% | 860 | 58.5% | ā<ā0.001 |
Tobacco Users | 665 | 46.3% | 714 | 48.6% | 0.215 |
Substance Abuse | 91 | 6.3% | 94 | 6.4% | 0.912 |
Diabetes mellitus | 347 | 24.1% | 298 | 20.3% | 0.014 |
COPD | 30 | 2.1% | 34 | 2.3% | 0.713 |
CHF | 48 | 3.3% | 59 | 4.0% | 0.315 |
HTN | 676 | 47.0% | 603 | 41.0% | 0.001 |
CKD | 77 | 5.4% | 51 | 3.5% | 0.013 |
ASA Class | |||||
ā1 | 36 | 2.5% | 37 | 2.5% | 0.999 |
ā2 | 814 | 56.6% | 875 | 59.5% | 0.113 |
ā3 | 577 | 40.2% | 547 | 37.2% | 0.097 |
ā4 | 10 | 0.7% | 8 | 0.5% | 0.485 |